Search Trials
Conditions
Learn
About

This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.

Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment | MicrobiomeTrials

← Back to trials

NCT07508956

Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2026-06-01Est. Completion: 2029-03-31

Enrollment target: 304 participants

Locations

Zhongshan Hospital, Fudan University, Shanghai, Shanghai Municipality, China

Contact

Xuefei Wang, MD, PhDwang.xuefei@zs-hospital.sh.cn +86 21 64041990

Other microbiome trials you might be interested in

Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric CancerRecruiting

Gastric Cancer

This project aims to evaluate the efficacy and safety of oral taurine supplementation combined with PD-1 inhibitor (serp…

Wuhan, ChinaEst. completion Jun 30, 2027

View Trial →

Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)Phase 2Completed

Gastric AdenocarcinomaMetastatic Gastric CancerMetastatic AdenocarcinomaAdvanced Gastric Carcinoma

For patients with advanced/metastatic gastric adenocarcinomas in progression after a first line chemotherapy comprising …

Dijon, FranceCompleted Jun 4, 2026

View Trial →

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.